Hedgehog pathway inhibition and the race against tumor evolution

Journal of Cell Biology

Volumn 199, Issue 2, 2012, Pages 193-197

  Atwood, Scott X ^a   Chang, Anne Lynn S ^a   Oro, Anthony E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYCLOPAMINE; GANT 58; GANT 61; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN INHIBITOR; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG; VISMODEGIB;

ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG POTENTIATION; HUMAN; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CEREBELLAR NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; VERATRUM ALKALOIDS;

ERINACEIDAE;

EID: 84869131742     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201207140     Document Type: Article

References (30)

1. Buonamici, S., J. Williams, M. Morrissey, A. Wang, R. Guo, A. Vattay, K. Hsiao, J. Yuan, J. Green, B. Ospina, et al. 2010. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2:51ra70. http://dx.doi.org/10.1126/scitranslmed.3001599
2. Callahan, C.A., T. Ofstad, L. Horng, J.K. Wang, H.H. Zhen, P.A. Coulombe, and A.E. Oro. 2004. MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev. 18:2724-2729. http://dx.doi.org/10.1101/gad.1221804
3. Chang, A.L., and A.E. Oro. 2012. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma patients. Arch. Dermatol. In press.
4. Chen, J.K., J. Taipale, K.E. Young, T. Maiti, and P.A. Beachy. 2002a. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA. 99:14071-14076. http://dx.doi.org/10.1073/pnas.182542899
5. Chen, J.K., J. Taipale, M.K. Cooper, and P.A. Beachy. 2002b. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16:2743-2748. http://dx.doi.org/10.1101/gad.1025302
6. Diaz, L.A. Jr., R.T. Williams, J. Wu, I. Kinde, J.R. Hecht, J. Berlin, B. Allen, I. Bozic, J.G. Reiter, M.A. Nowak, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 486:537-540.
7. Dijkgraaf, G.J.P., B. Alicke, L. Weinmann, T. Januario, K. West, Z. Modrusan, D. Burdick, R. Goldsmith, K. Robarge, D. Sutherlin, et al. 2011. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 71:435-444. http://dx.doi.org/10.1158/0008-5472.CAN-10-2876
8. Epstein, E.H. 2008. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer. 8:743-754. http://dx.doi.org/10.1038/nrc2503
9. Gomez-Ospina, N., A.L.S. Chang, K. Qu, and A.E. Oro. 2012. Translocation affecting sonic hedgehog genes in basal-cell carcinoma. N. Engl. J. Med. 366:2233-2234. http://dx.doi.org/10.1056/NEJMc1115123
10. Hildebrandt, F., T. Benzing, and N. Katsanis. 2011. Ciliopathies. N. Engl. J. Med. 364:1533-1543. http://dx.doi.org/10.1056/NEJMra1010172
11. Huangfu, D., A. Liu, A.S. Rakeman, N.S. Murcia, L. Niswander, and K.V. Anderson. 2003. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature. 426:83-87. http://dx.doi.org/10.1038/nature02061
12. Hui, C.-C., and S. Angers. 2011. Gli proteins in development and disease. Annu. Rev. Cell Dev. Biol. 27:513-537. http://dx.doi.org/10.1146/annurev-cellbio-092910-154048
13. Humke, E.W., K.V. Dorn, L. Milenkovic, M.P. Scott, and R. Rohatgi. 2010. The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. Genes Dev. 24:670-682. http://dx.doi.org/10.1101/gad.1902910
14. Keady, B.T., R. Samtani, K. Tobita, M. Tsuchya, J.T. San Agustin, J.A. Follit, J.A. Jonassen, R. Subramanian, C.W. Lo, and G.J. Pazour. 2012. IFT25 links the signal-dependent movement of Hedgehog components to intraflagellar transport. Dev. Cell. 22:940-951. http://dx.doi.org/10.1016/j.devcel.2012.04.009
15. Kim, J., J.J. Lee, J. Kim, D. Gardner, and P.A. Beachy. 2010. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. USA. 107:13432-13437. http://dx.doi.org/10.1073/pnas.1006822107
16. Lauth, M., Å. Bergström, T. Shimokawa, and R. Toftgård. 2007. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA. 104:8455-8460. http://dx.doi.org/10.1073/pnas.0609699104
17. Loeb, L.A. 2011. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer. 11:450-457. http://dx.doi.org/10.1038/nrc3063
18. LoRusso, P.M., C.M. Rudin, J.C. Reddy, R. Tibes, G.J. Weiss, M.J. Borad, C.L. Hann, J.R. Brahmer, I. Chang, W.C. Darbonne, et al. 2011. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17:2502-2511. http://dx.doi.org/10.1158/1078-0432.CCR-10-2745
19. Misale, S., R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, et al. 2012. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486:532-536.
20. National Cancer Institute. 2010. Cancer Trends Progress Report. 2009/2010 Update. http://progressreport.cancer.gov (accessed May 28, 2012).
21. Update. http://progressreport.cancer.gov (accessed May 28, 2012). Riobó, N.A., K. Lu, X. Ai, G.M. Haines, and C.P. Emerson Jr. 2006. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. USA. 103:4505-4510. http://dx.doi.org/10.1073/pnas.0504337103
22. Robarge, K.D., S.A. Brunton, G.M. Castanedo, Y. Cui, M.S. Dina, R. Goldsmith, S.E. Gould, O. Guichert, J.L. Gunzner, J. Halladay, et al. 2009. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19:5576-5581. http://dx.doi.org/10.1016/j.bmcl.2009.08.049
23. Sekulic, A., M.R. Migden, A.E. Oro, L. Dirix, K.D. Lewis, J.D. Hainsworth, J.A. Solomon, S. Yoo, S.T. Arron, P.A. Friedlander, et al. 2012. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366:2171-2179. http://dx.doi.org/10.1056/NEJMoa1113713
24. Tang, J.Y., J.M. Mackay-Wiggan, M. Aszterbaum, R.L. Yauch, J. Lindgren, K. Chang, C. Coppola, A.M. Chanana, J. Marji, D.R. Bickers, and E.H. Epstein Jr. 2012. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366:2180-2188. http://dx.doi.org/10.1056/NEJMoa1113538
25. Tukachinsky, H., L.V. Lopez, and A. Salic. 2010. A mechanism for vertebrate Hedgehog signaling: recruitment to cilia and dissociation of SuFu-Gli protein complexes. J. Cell Biol. 191:415-428. http://dx.doi.org/10.1083/jcb.201004108
26. Varjosalo, M., and J. Taipale. 2008. Hedgehog: functions and mechanisms. Genes Dev. 22:2454-2472. http://dx.doi.org/10.1101/gad.1693608
27. Von Hoff, D.D., P.M. LoRusso, C.M. Rudin, J.C. Reddy, R.L. Yauch, R. Tibes, G.J. Weiss, M.J. Borad, C.L. Hann, J.R. Brahmer, et al. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361:1164-1172. http://dx.doi.org/10.1056/NEJMoa0905360
28. Wang, Y., Q. Ding, C.-J. Yen, W. Xia, J.G. Izzo, J.-Y. Lang, C.-W. Li, J.L. Hsu, S.A. Miller, X. Wang, et al. 2012. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21:374-387. http://dx.doi.org/10.1016/j.ccr.2011.12.028
29. Weiss, G.J., and R.L. Korn. 2012. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. In press.
30. Yauch, R.L., G.J.P. Dijkgraaf, B. Alicke, T. Januario, C.P. Ahn, T. Holcomb, K. Pujara, J. Stinson, C.A. Callahan, T. Tang, et al. 2009. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 326:572-574. http://dx.doi.org/10.1126/science.1179386